Scott M. Rocklage is a living legend having worked with over ten publicly-traded pharmaceutical firms to date. Prof. Rocklage joined 5AM Venture firm quickly working his way to be named as a managing partner at 5AM Ventures barely a year later in 2004.
Scott will forever go down in history as a giant, especially bearing in mind that he has secured well over 25 U.S patents so far.
Interestingly, Scott rubbed shoulders with the eminent scientist and the Chemistry Nobel Prize winner, Richard R. Schrock during his MIT days. The seasoned researcher and investor completed two Chemistry degrees at MIT and at UCLA Berkley.
Scott Rocklage is a vastly decorated drug development researcher with a record tally of over 100 peer-reviewed medical journals published.
Running 5AM Ventures
Dr. Rocklage spends most of his day running 5AM Ventures from their headquarters in Boston, MA. 5AM specializes is a startup incubator company designed to assist the young, broke and inexperienced entrepreneurs as they build their ideas and concepts.
For three decades, Scott took on the important positions of President, CEO, and Chairman in a barrage of successful pharmaceutical firms in the States. Here are the NASDAQ and Dow Jones Traded Companies he’s led and his positions:-
- CEO and Chairman of Cubist Pharmaceuticals
- Chairman at Relypsa and Novira Inc.
- Chairperson of Kinestral, Cidara and Rennovia Inc.
- Executive Chairman at Semprus, Miikana, and Ilypsa
- Previous Companies Served
Dr. Scott Rocklage is a shrewd investor renowned for his capital raising prowess. Over the course of his career, he’s succeeded to raise hundreds of millions of seed money to fund vital departments in the pharmaceutical firms he served. Read more: Scott Rocklage | Crunchbase and Scott Racklage | Bloomberg
As the Chairman of Pulmatrix Inc., he managed to breathe new life into the firm’s R&D department by raising an estimated $10M. In 2012, the brilliant investor repeated the same by helping Novira Inc. raise $23M in finances. Last year, Scott Rocklage oversaw the negotiations that led to Aprea AB Inc. to get $51M from investors.
Dr. Rocklage has devoted personal resources and energy to chase down viable cancer cures.
No wonder, he stated that he’s overly excited by how new technology is aiding researchers in their quest for the ever-elusive cancer treatment and cure. Click here to read the rest of the captivating interview Dr. Scott did with Ideasmensch.com